Cargando…

Activation of Hypoxia‐Inducible Factor‐2 in Adipocytes Results in Pathological Cardiac Hypertrophy

BACKGROUND: Obesity can cause structural and functional abnormalities of the heart via complex but largely undefined mechanisms. Emerging evidence has shown that obesity results in reduced oxygen concentrations, or hypoxia, in adipose tissue. We hypothesized that the adipocyte hypoxia‐signaling path...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Qun, Huang, Yan, Booth, Carmen J., Haase, Volker H., Johnson, Randall S., Celeste Simon, M., Giordano, Frank J., Yun, Zhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3886757/ https://www.ncbi.nlm.nih.gov/pubmed/24326162 http://dx.doi.org/10.1161/JAHA.113.000548

Ejemplares similares

The Hypoxia-Inducible Factor Pathway in Adipocytes: The Role of HIF-2 in Adipose Inflammation and Hypertrophic Cardiomyopathy
por: Lin, Qun, et al.
Publicado: (2015)

Role of adipocyte-derived lipoprotein lipase in adipocyte hypertrophy
por: Gonzales, Amanda M, et al.
Publicado: (2007)

Functions of Autophagy in Pathological Cardiac Hypertrophy
por: Li, Zhenhua, et al.
Publicado: (2015)

VCP represses pathological cardiac hypertrophy
por: Zhou, Ning, et al.
Publicado: (2017)

Vesicles Shed by Pathological Murine Adipocytes Spread Pathology: Characterization and Functional Role of Insulin Resistant/Hypertrophied Adiposomes
por: Tamara, Camino, et al.
Publicado: (2020)

Mitochondria in Pathological Cardiac Hypertrophy Research and Therapy
por: Yang, Dan, et al.
Publicado: (2022)

CIB1 is a Regulator of Pathological Cardiac Hypertrophy
por: Heineke, Joerg, et al.
Publicado: (2010)

The Role of CD147 in Pathological Cardiac Hypertrophy Is Regulated by Glycosylation
por: Zhong, Fang-yuan, et al.
Publicado: (2022)

Tripartite motif 32 prevents pathological cardiac hypertrophy
por: Chen, Lijuan, et al.
Publicado: (2016)

Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome
por: Kusaka, Hiroaki, et al.
Publicado: (2016)

Targeted deletion of Tcf7l2 in adipocytes promotes adipocyte hypertrophy and impaired glucose metabolism
por: Geoghegan, Gisela, et al.
Publicado: (2019)

Increased Adipocyte Hypertrophy in Patients with Nascent Metabolic Syndrome
por: Jialal, Ishwarlal, et al.
Publicado: (2023)

Inhibition of Adipose Tissue Beiging by HIV Integrase Inhibitors, Dolutegravir and Bictegravir, Is Associated with Adipocyte Hypertrophy, Hypoxia, Elevated Fibrosis, and Insulin Resistance in Simian Adipose Tissue and Human Adipocytes
por: Ngono Ayissi, Kenza, et al.
Publicado: (2022)

Dietary-challenged mice with Alzheimer-like pathology show increased energy expenditure and reduced adipocyte hypertrophy and steatosis
por: Schreyer, Stefanie, et al.
Publicado: (2021)

Suppressor of IKKɛ is an essential negative regulator of pathological cardiac hypertrophy
por: Deng, Ke-Qiong, et al.
Publicado: (2016)

Caspase Cleavage of Gelsolin Is an Inductive Cue for Pathologic Cardiac Hypertrophy
por: Putinski, Charis, et al.
Publicado: (2018)

Mitochondrial pyruvate carrier abundance mediates pathological cardiac hypertrophy
por: Fernandez-Caggiano, Mariana, et al.
Publicado: (2020)

Non-Coding RNAs in the Therapeutic Landscape of Pathological Cardiac Hypertrophy
por: Silva, Joana, et al.
Publicado: (2022)

ANGPTL8 is a negative regulator in pathological cardiac hypertrophy
por: Hu, Lin, et al.
Publicado: (2022)

Slowing Heart Rate Protects Against Pathological Cardiac Hypertrophy
por: Sebastian, Sonia, et al.
Publicado: (2022)

Myocardial Hypertrophy Overrides the Angiogenic Response to Hypoxia
por: Choi, Yeong-Hoon, et al.
Publicado: (2008)

Mirtazapine Reduces Adipocyte Hypertrophy and Increases Glucose Transporter Expression in Obese Mice
por: Wu, Ching-Feng, et al.
Publicado: (2020)

Multiple short‐chain dehydrogenases/reductases are regulated in pathological cardiac hypertrophy
por: Roussel, Elise, et al.
Publicado: (2018)

Carvacrol Ameliorates Pathological Cardiac Hypertrophy in Both In-vivo and In-vitro Models
por: Jamhiri, Mohabbat, et al.
Publicado: (2019)

Divergent and Overlapping Roles for Selected Phytochemicals in the Regulation of Pathological Cardiac Hypertrophy
por: Evans, Levi, et al.
Publicado: (2021)

Targeting miR-30d reverses pathological cardiac hypertrophy
por: Li, Jin, et al.
Publicado: (2022)

Central role for BRAF in cardiac hypertrophy: rethinking the pathological–physiological divide
por: Altara, Raffaele, et al.
Publicado: (2023)

Cardiac Hypertrophy
por: DaCosta,
Publicado: (1891)

Hypoxia-inducible factor signaling in the development of kidney fibrosis
por: Haase, Volker H
Publicado: (2012)

Macadamia Oil Supplementation Attenuates Inflammation and Adipocyte Hypertrophy in Obese Mice
por: Lima, Edson A., et al.
Publicado: (2014)

Lysosomal Cathepsin D contributes to cell death during adipocyte hypertrophy
por: Eguchi, Akiko, et al.
Publicado: (2013)

Associations between subcutaneous adipocyte hypertrophy and nonalcoholic fatty liver disease
por: Holmer, Magnus, et al.
Publicado: (2022)

Hypoxia Decreases Insulin Signaling Pathways in Adipocytes
por: Regazzetti, Claire, et al.
Publicado: (2009)

Histone lysine dimethyl-demethylase KDM3A controls pathological cardiac hypertrophy and fibrosis
por: Zhang, Qing-Jun, et al.
Publicado: (2018)

Loss of Endothelial Hypoxia Inducible Factor‐Prolyl Hydroxylase 2 Induces Cardiac Hypertrophy and Fibrosis
por: Dai, Zhiyu, et al.
Publicado: (2021)

Cardiac LXRα protects against pathological cardiac hypertrophy and dysfunction by enhancing glucose uptake and utilization
por: Cannon, Megan V, et al.
Publicado: (2015)

Increased afterload induces pathological cardiac hypertrophy: a new in vitro model
por: Hirt, Marc N., et al.
Publicado: (2012)

Novel genomic targets of valosin-containing protein in protecting pathological cardiac hypertrophy
por: Zhou, Ning, et al.
Publicado: (2020)

Ganoderma lucidum polysaccharides attenuates pressure-overload-induced pathological cardiac hypertrophy
por: Zhen, Changlin, et al.
Publicado: (2023)

Author Correction: Suppressor of IKKɛ is an essential negative regulator of pathological cardiac hypertrophy
por: Deng, Ke-Qiong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ovre62mtrpji6up5pbtflhrrsb